Sells YUTREPIA, an inhaled treprostinil medicine for people with pulmonary arterial hypertension, and develops inhaled medicines for respiratory and vascular diseases.
10-K for FY2025, filed Mar 5, 2026
YUTREPIA sales come from supplying specialty pharmacies and a specialty distributor, with sales counted when the product is delivered. Service revenue came from sharing profit on Sandoz’s Treprostinil Injection sales; Liquidia has since ended that promotion agreement.
10-K for FY2025, filed Mar 5, 2026 8-K, filed Oct 14, 2026In the second quarter of 2025, YUTREPIA became available to patients with a prescription in the U.S. and we commenced commercial sales to…View ↗
We have determined that the delivery of YUTREPIA to our customers constitutes a single performance obligation. There are no other promises…View ↗
We primarily generate service revenue pursuant to the Promotion Agreement, under which we receive a 50% share in the profit derived from…View ↗
In connection with the settlement, Liquidia entered into agreements with the parties with interests in the antitrust litigation related to…View ↗
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by product or service ↗$158.3M
10-K for FY2025, filed Mar 5, 2026
$158.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales, net
Sold outright
10-K for FY2025, filed Mar 5, 2026 |
94% |
Product sales, net, FY2025
$148.3M Sources
|
Sold outright |
|
Service revenue, net
|
6.3% |
Service revenue, net, FY2025
$10M Sources
|
Liquidia sells YUTREPIA to specialty pharmacies and a specialty distributor, which in turn sell it to patients, clinics, hospitals, and federal healthcare programs. Its field force also calls on healthcare providers and distribution and reimbursement stakeholders.
10-K for FY2025, filed Mar 5, 2026
No. It lost $68.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$236.3MView ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
Open tableView ↗
8-K, filed Oct 14, 2026
Under the terms of the Settlement Agreement, the Company will continue to market, sell and promote YUTREPIA® (treprostinil) inhalation…View ↗
Growing. Revenue grew 12.3x in 4 years, from $12.9M in FY2021 to $158.3M in FY2025, about 87% a year.
YUTREPIA launch
The older report described YUTREPIA as a lead candidate with tentative FDA approval; the latest says it received approval and began commercialization, shifting it from a candidate awaiting approval to a marketed medicine.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Mar 5, 2026Our lead product candidate is YUTREPIA for the treatment of PAH. YUTREPIA is an inhaled dry powder formulation of treprostinil designed…View ↗
YUTREPIA is an inhaled dry powder formulation of treprostinil designed with our proprietary PRINT technology, a particle engineering…View ↗
Competes with Johnson & Johnson, Gilead Sciences, Bayer Schering Pharma, Merck &, United Therapeutics, MannKind, Actelion, Teva, Par Pharmaceutical, Dr. Reddy’s, Alembic, Corsair Pharma, and Insmed
10-K for FY2025, filed Mar 5, 2026Our products and development programs directed toward the treatment of PAH compete with several approved classes of drugs in clinically…View ↗
Loading...